# Milestone Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/milestone-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Canada
- Website: www.milestonepharma.com
- Total disclosed funding: $88M
- Latest round: Series C (Aug 1, 2017)
- Investors on record: 10

## About

Based in Quebec, Canada, and founded in 2005 by founder Philippe Douville, Milestone Pharmaceuticals, Inc. operates as a biopharmaceutical company providing the treatment of paroxysmal supraventricular tachycardia. As of 2024, the firm is listed on NASDAQ with ticker symbol MIST. In February 2024, Milestone Pharmaceuticals, Inc. raised USD 30 million in a private placement, selling 16.66 million shares at USD 1.50 per share in the NASDAQ. The company has granted the underwriters a 30-day option to purchase up to 3,000,000 common shares at the public offering price.

Milestone Pharmaceuticals, Inc. developed an investigational product known as etripamil, which is a novel calcium channel blocker delivered as a nasal spray. The company’s product is designed for the acute at-home treatment of PSVT and AFib-RVR, allowing patients to manage their heart rhythm disturbances wherever they may be. In addition, the firm submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, highlighting its potential to transform the standard of care for these conditions.

The company plans to use the funding from February 2024 to use the net proceeds from the Offering to continue the development of etripamil in its lead indication of paroxysmal supraventricular tachycardia (PSVT) and its subsequent indication of atrial fibrillation with rapid ventricular rate (AFib-RVR), as well as for working capital and other general corporate purposes.

## Funding rounds

- Series C, Aug 1, 2017, $55M — Domain Associates, GO Capital, BDC Capital, Pappas Capital, Fonds de Solidarité des Travailleurs du Québec, Tekla Capital Management, Forbion, Novo Holdings
- Series B, Jun 15, 2015, $17M — Domain Associates, BDC Capital, Pappas Capital, Inovia Capital, Fonds de Solidarité des Travailleurs du Québec
- Series B, Jun 13, 2011, $13M — BDC Capital, Pappas Capital, Inovia Capital, Fonds de Solidarité des Travailleurs du Québec, Fonds Bio-Innovation s.e.c
- Seed, Aug 7, 2007, $2.6M — Inovia Capital, Fonds Bio-Innovation s.e.c

## Investors

- Inovia Capital (https://capitalatlas.ai/funds/inovia-capital) — Seed, Series B
- Fonds Bio-Innovation s.e.c — Seed, Series B
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series B, Series C
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series B, Series C
- Fonds de Solidarité des Travailleurs du Québec — Series B, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C
- GO Capital — Series C
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C
- Novo Holdings — Series C